RLAY
NASDAQ
US
Relay Therapeutics, Inc. - Common Stock
$12.54
▲ +$1.77
(+16.43%)
Vol 8.9M
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$1.5B
ROE
-42.9%
Margin
-1764.5%
D/E
0.00
Beta
1.57
52W
$2–$9
Wall Street Consensus
18 analysts · Apr 20268
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
94.4%
Buy Rating
Price Chart
Similar Stocks
KOD
Kodiak Sciences Inc
$1.7B
IMNM
Immunome Inc
$2.4B
SRPT
Sarepta Therapeutics Inc
$2.3B
BCRX
BioCryst Pharmaceuticals Inc
$1.6B
GRAL
Grail Inc
$3.3B
MLYS
Mineralys Therapeutics Inc
$2.9B
SNDX
Syndax Pharmaceuticals Inc
$1.8B
DAWN
Day One Biopharmaceuticals Inc
$956.9M
ADMA
ADMA Biologics Inc
P/E 20.7
$4.3B
RARE
Ultragenyx Pharmaceutical Inc
$2.2B
Earnings
Beat rate: 75.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.41 | $-0.32 | +$0.09 |
| Sep 2025 | $-0.42 | $-0.43 | $-0.01 |
| Jun 2025 | $-0.50 | $-0.41 | +$0.09 |
| Mar 2025 | $-0.50 | $-0.46 | +$0.04 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -41.5% | -41.5% | -41.5% | -41.5% | -42.9% | -42.9% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -10395.1% | -1764.5% | -1764.5% | -1764.5% | -1764.5% | -1764.5% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 20.92 | 20.92 | 20.92 | 20.92 | 19.14 | 19.14 |
Key Ratios
ROA (TTM)
-38.8%
P/S (TTM)
175.48
P/B
0.9
EPS (TTM)
$-1.75
CF/Share
$-2.64
Rev Growth 3Y
+48.9%
52W High
$9.04
52W Low
$1.78
$1.78
52-Week Range
$9.04
How does RLAY compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
RLAY valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
175.5
▲
1266%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
0.9
▼
64%
below
peers
(2.5)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
RLAY profitability vs Biotechnology peers
ROE
-42.9%
▲
36%
above
peers
(-67.3%)
vs Peers
vs Industry
Below avg
Net margin
-1764.5%
▼
515%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-38.8%
▲
17%
above
peers
(-46.7%)
vs Peers
vs Industry
Below avg
RLAY financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
19.1
▲
331%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.6
▲
62%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
RLAY fundamentals radar
RLAY
Peer median
Industry
RLAY profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
RLAY vs peers: key metrics
Latest News
No related news yet